AbbVie Will Pay Up To $840M For Ablynx Licensing Deal
Under the deal, AbbVie will pay Ablynx $175 million upfront to fund additional clinical development for Ablynx's ALX-0061 nanobody and will shell out up to $665 million if certain development, regulatory, commercial and sale-based milestones are hit, the companies said.
Ablynx Chairman and CEO Edwin Moses said in...
Already a subscriber? Click here to login